1. Vital Synthesis plant start-up - The Dahej specialty chemicals plant received its final GPCB consent on June 10, 2026, permitting 173 products across 11 groups, with commercial production expected within FY26. This adds a second earnings leg to the current phosphorus business, with the consent order already in hand and the plant in final completion.
2. P2S5 customer approvals - Management is obtaining customer approval for Phosphorus Pentasulfide, with the plant at Dahej already operational. Approvals would convert existing capacity into revenue, a direct near-term trigger given the company's current EBITDA base of ₹10 cr.
3. PCl5 lithium-ion electrolyte - Phosphorus Pentachloride has an emerging application in Lithium Hexafluorophosphate, an electrolyte for EV batteries. This opens a demand pool far larger than the current specialty chemical market, though it remains an application in development rather than a signed order.
4. PPA BIS certification - BIS registration for Polyphosphoric Acid was granted October 10, 2025, valid through October 2027. Certification removes a regulatory barrier to selling PPA in India, supporting volume growth in an existing product line.
5. NSE Main Board migration - Trading on the NSE Main Board commenced March 11, 2026, after final listing approval. Main Board listing widens the investor base and improves liquidity, which can support equity-funded growth for the Dahej capex pipeline.